Does Tysabri reverse the symptoms of MS?
DUBLIN, April 29 (Reuters) – Elan’s (ELN.I) Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec (BIIB.O) said on Wednesday, boosting Elan’s shares 10 percent. Data released by the companies at the American Academy of Neurology showed Tysabri promoted the regeneration of the protein coat that protects nerve fibres and whose damage causes the symptoms of multiple sclerosis. “This provides more evidence that Tysabri may not just slow down the progress of MS but also may be able to reverse the damage caused by the disease,” Goodbody analyst Ian Hunter said in a note. Sources: http://www.reuters.
Elan, Biogen Idec Study Reveals Positive Results For Tysabri Published:31-May-2009 By Staff Reporter Elan and Biogen Idec has announced that Tysabri (natalizumab) has successfully improved health-related quality of life (QOL) in patients suffering from Crohn’s Disease (CD), who had previously been exposed to or failed anti-TNF therapy versus placebo. These results were obtained from subset analysis of the Phase 3 evaluation of Natalizumab as Continuous Therapy (ENACT-2) and efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) trials. In the 12-week ENCORE induction trial, patients receiving Tysabri (who had failed previous anti-TNF therapy) achieved statistically significant improvements compared with those receiving placebo on the total IBDQ scale and the two summary scales of the SF-36, the Physical Component Summary and the Mental Component Summary. Brian Feagan, M.D. of the Robarts Research Institute detailing the effects of Tysabri on the full sample of patie
Data released by the companies at the American Academy of Neurology showed Tysabri promoted the regeneration of the protein coat that protects nerve fibres and whose damage causes the symptoms of multiple sclerosis. “This provides more evidence that Tysabri may not just slow down the progress of MS but also may be able to reverse the damage caused by the disease,” Goodbody analyst Ian Hunter said in a note. Tysabri, which is given by infusion, is the most effective drug on the market, reducing the relapse rate in patients with multiple sclerosis by 68 percent. But sales have been crimped because of its link with progressive multifocal leukoencephalopathy, or PML, a potentially deadly brain infection. Sources: http://uk.reuters.
